API
< Back to all clusters
[HEALTH] · Spain · 2 sources

started · updated

Researchers test MiS1 peptide treatment for diabetic retinopathy in mice

A research team led by the Complutense University of Madrid, in collaboration with the Fundación Jiménez Díaz, has reported promising results using a MiS1-based treatment to address diabetic retinopathy in mice. The study, published in Investigative Ophthalmology & Visual Science, focuses on the early stages of the disease, specifically targeting the inflammatory responses and nerve cell damage caused by type 2 diabetes.

MiS1 is a peptide designed to mimic the action of the SOCS1 protein, which helps regulate inflammatory signals. In the seven-week study, untreated diabetic mice showed neurodegeneration, including retinal thinning and a loss of retinal ganglion cells. In contrast, mice treated with MiS1 exhibited less retinal thinning and more stable microglia cell structures. This research explores the potential for developing future drugs to protect the retina before evident vascular lesions occur.

Entities

Complutense University of Madrid · Fundación Jiménez Díaz · Investigative Ophthalmology & Visual Science